Hydrocortisone Use After Etomidate in Intensive Care

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

the objective of the study is to assess the value of substitution with 200mg/24h of hydrocortisone for 48 hours for patients in intensive care who have received a single injection of etomidate

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Grenoble
• Treatments: Cortisol succinate; Etomidate; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate

Criteria

Inclusion Criteria:

• Patients who received an unique injection of etomidate in pre-hospital situation or at "déchocage" in the previous 6 hours.

• informed consent signed by the patient or the reliable person

• affiliation to a regime of social security

Exclusion Criteria:

• persons aimed at the articles L. 1121-5 à L. 1121-8 of the french code of public health

• toxic shock requiring a treatment by HSHC inn accordance with the criteria of Annane et Al. [13]

• purpura fulminans

• chronicle suprarenal insufficiency

• patients likely to present an acute suprarenal insufficiency : current treatment with antifungal : ketoconazole or fluconazole, known HIV infection, Sheehan syndrome

• corticotherapy in the 6 last months

• initiation of hydrocortisone therapy out of the study

• survival estimated at less than 48 hours

• no benefits of social security

• refusal to participate by patient or reliable person